IJCEP Copyright © 2007-All rights reserved.
Int J Clin Exp Pathol 2013;6(11):2644-2650

Letter to Editor
Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung
cancer: a systematic reviewe

Hongying Qu, Rong Li, Zhiyue Liu, Junyi Zhang, Rongcheng Luo

Cancer Center, Southern Medical University, Guangzhou, 510315, China; Tranditional Chinese Medicine-Integrated Hospital, Southern Medical
University, Guangzhou, 510315, China; Department of Oncology, The First Affiliated Hospital, Baotou Medical College, Baotou, 014010, China;
Inner Mongolia Medical University, Huhhot, 010110, China. Equal contributors.

Received August 21, 2013; Accepted September 17, 2013; Epub October 15, 2013; Published November 1, 2013

Abstract: Objective: To investigate the correlation between CD133-positive non-small cell lung cancer (NSCLC) and clinicopathological
features and its impact on survival. Methods: A search in the Pubmed, Embase and Wanfang databases (up to July 15, 2013) was performed.
Only articles in which CD133 antigen was detected in situ localization by immunohistochemical staining were included. This meta-analysis
was done using RevMan 5.2 software. Outcomes included overall survival and various clinicopathological features. Results: A total of 1004
NSCLC patients from 11 studies were included. Meta-analysis showed that CD133 expression patients had a significant worse 5-year overall
survival compared to the low expression ones (RR = 3.19, 95% CI: 2.05-4.98, P<0.0001 fixed random). With respect to clinicopathological
features, CD133 expression by IHC method was closely correlated with tumor T stage (OR = 0.91, 95% CI: 0.59-1.39, P = 0.67 fixed-effect) and
tumor grade (OR = 1.20, 95% CI: 0.80-1.79, P = 0.37 fixed-effect). Conclusion: CD133-positive NSCLC patients had worse prognosis, and was
associated with common clinicopathological poor prognostic factors. (IJCEP1308056).

Keywords: Non-small cell lung cancer, cancer stem cells, CD133, prognosis

Address correspondence to: Junyi Zhang and Rongcheng Luo, Cancer Center, Southern Medical University, Guangzhou, 510315, China;
Tranditional Chinese Medicine-Integrated Hospital, Southern Medical University, No. 13, Shiliugang Road, Haizhu District, Guangzhou, 510315,
China. Tel: 8602061650051; Fax: 8602061650054; E-mail: junyi6352@126.com (Junyi Zhang); rongchengluo72@126.com (Rongcheng Luo)